Thomas Mccourt Buys Shares of PLRX $PLRX
Key Points
- Thomas Mccourt bought 70,000 shares of Pliant Therapeutics, Inc. ($PLRX).
- $PLRX last traded around $1.13.
Thomas Mccourt, insider at Pliant Therapeutics, Inc. ($PLRX), bought 70,000 shares at an average price of $0.00. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Pliant Therapeutics, Inc. ($PLRX) Stock
Pliant Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.